← Back to patent-cliff list
APL-3007
Tier C — Watch / tradeAPL-3007
Apellis Pharmaceuticals Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：C3
Indications (approved)：地图状萎缩
Regional status
US
Phase II
2025-06-23
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of APL-3007?
Approved indications include: 地图状萎缩.
When does the APL-3007 patent expire?
No public expiry year is available for APL-3007 yet; this page updates once verified.
How do I get a quote for APL-3007 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30